Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Genomic DNA loci with partial complementarity to the PE3max pegRNA or nicking sgRNA refer to unintended sites in the genome where prime editing components may bind and exert activity. Prime editing (PE) utilizes a Cas9 nickase fused to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA) and often an auxiliary nicking sgRNA in PE3 or PE3max systems to install precise genetic changes (Anzalone et al., 2019, Nature). Although prime editing is generally considered more precise than standard CRISPR-Cas9, the guide RNAs can still hybridize with off-target sequences that possess high sequence homology to the intended target (Kim et al., 2020, Nature Biotechnology). Interaction at these loci can result in permanent, unintended mutations, including insertions, deletions, or substitutions, which may disrupt tumor suppressor genes or activate oncogenes (Chen et al., 2021, Cell). These off-target effects represent a significant hurdle in the development of safe gene therapies, as they can lead to unpredictable cellular phenotypes or long-term genotoxicity. Monitoring these loci using high-throughput sequencing methods is essential for assessing the specificity of a prime editing therapeutic (Doman et al., 2020, Nature Biotechnology). Consequently, identifying and characterizing these loci is a fundamental requirement for the clinical development of prime editing therapies to ensure genomic integrity and patient safety.
Unintended hybridization of guide RNAs to genomic sequences with partial complementarity, leading to Cas9-mediated DNA nicking and subsequent reverse transcription or DNA repair-mediated mutagenesis at non-target sites.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target genomic DNA loci (Prime Editing) (Off-target sites).